Development and applications of oncolytic Maraba virus vaccines

Area of Science:

• Oncolytic virotherapy
• Cancer immunotherapy
• Vaccine development

Background:

• The MG1 strain of Maraba vesiculovirus exhibits oncolytic activity through direct cytotoxicity and immune stimulation.
• Enhancing tumor-specific T-cell responses and long-lasting memory is crucial for effective cancer vaccines.

Purpose of the Study:

• To develop a prime-boost cancer vaccine strategy using an adenoviral vector and the oncolytic MG1 virus.
• To evaluate the efficacy and safety of this combined vaccination approach.

Main Methods:

• Replication-incompetent adenoviral [Ad] vector and oncolytic MG1 virus were engineered to express a common tumor antigen.
• A prime-boost vaccination regimen was administered, involving Ad priming followed by MG1 boosting.
• Immune responses and survival were assessed in preclinical murine cancer models.
• Safety was evaluated in nonhuman primates, and clinical trials were initiated.

Main Results:

• The Ad:MG1 prime-boost vaccination induced robust tumor-specific immune responses.
• This strategy significantly prolonged survival across various murine cancer models.
• The safety profile in nonhuman primates was validated, supporting clinical translation.

Conclusions:

• The MG1 oncolytic vaccine, when used in an Ad prime-boost strategy, represents a promising approach for cancer immunotherapy.
• This strategy effectively enhances anti-tumor immunity and has progressed to clinical trials in cancer patients.